Monday, September 21, 2009 8:19:30 AM
Press Release
Source: Incyte Corporation
On Monday September 21, 2009, 8:00 am EDT
Companies:Incyte Corporation
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY - News) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month Phase IIb trial comparing three once-daily doses of topical INCB18424 to vehicle in 200 patients with mild-to-moderate psoriasis. In the trial patients treated with INCB18424 had a statistically significant improvement over placebo in the reduction in total lesion score (erythema + scaling + thickness), which was the primary efficacy endpoint of the trial. Statistical significance was also achieved for the secondary endpoints: the Physician Global Assessment score and the Psoriasis Area and Severity Index score. INCB18424 was well tolerated at all doses and no clinically significant effects were noted in hematology or other laboratory parameters.
Paul Friedman, M.D., Incyte's President and CEO, will review these top-line clinical trial results during his corporate presentation at 12:00 pm (ET) today at the 2009 UBS Global Life Sciences Conference.
Dr. Friedman stated, “Our JAK1/JAK2 inhibitor was designed to block signaling from multiple key cytokines implicated in psoriasis and it is gratifying to see that topical INCB18424 met the primary and secondary endpoints in this three-month Phase IIb trial. We believe the positive safety and efficacy results achieved with this new mechanism of action have the potential to differentiate topical INCB18424 from the topical corticosteroids and vitamin D analogues which are limited by their duration of use and/or their tolerability profile.”
Incyte intends to present full results from this Phase IIb trial at an appropriate future scientific meeting.
To access today’s presentation at the UBS conference, please go to www.incyte.com under Investor Relations, Events and Webcasts. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. A replay of the presentation will also be available.
Recent INCY News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/14/2024 10:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:15:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:17:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:17:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:16:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:16:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:14:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:13:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 01:05:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 06/13/2024 12:16:08 PM
- Incyte Announces Final Results of Tender Offer • Business Wire • 06/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 08:59:05 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 06/11/2024 12:16:08 PM
- Incyte Announces Preliminary Results of Tender Offer • Business Wire • 06/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 04:25:08 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 08:40:39 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 06/04/2024 09:29:17 PM
- Incyte Completes Acquisition of Escient Pharmaceuticals • Business Wire • 05/30/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/30/2024 07:12:24 PM
- Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings • Business Wire • 05/21/2024 05:15:00 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/21/2024 12:00:00 PM
- Incyte präsentiert Daten aus seinem Onkologie-Portfolio beim Jahrestreffen 2024 der ASCO und beim EHA2024 Congress • Business Wire • 05/16/2024 01:45:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM